NEW YORK (GenomeWeb News) – Shares of Sequenom were up nearly 34 percent, to $27.50, in mid-afternoon trading today after the company disclosed yesterday that its SEQureDx test for Down syndrome successfully tested for Trisomy 21 in 219 patients with no false positives or negatives.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.